You are here:

  1. Home
  2. NICE Guidance
  3. Conditions and diseases
  4. Neurological conditions
  5. Multiple sclerosis

Multiple sclerosis in adults: management

  • NICE guideline
  • Reference number: NG220
  • Published:  22 June 2022
  • Guidance
  • Tools and resources
  • Information for the public
  • Evidence
  • History
Download (PDF)

Evidence reviews – June 2022

The following documents contain the evidence that was used to develop the recommendations:

  • Committee discussion for diagnostic criteria for multiple sclerosis; possible multiple sclerosis; neuromyelitis optica and clinically isolated syndrome
  • Information and support for patients (including people who may become pregnant), their families and carers
  • Coordination of care: the role of MS nurse specialists and other healthcare professionals
  • Non-pharmacological management of fatigue
  • Appendices for non-pharmacological management of fatigue
  • Pharmacological management of fatigue
  • Pharmacological management of mobility problems
  • Pharmacological management of spasticity
  • Non-pharmacological management of pain
  • Non-pharmacological management of memory and cognitive problems
  • Appendices for non-pharmacological management of memory and cognitive problems
  • Pharmacological management of ataxia and tremor

Other supporting evidence

  • Cost-utility analysis: Fampridine for the treatment of MS mobility
  • Full guideline – October 2014
 

This page was last updated: 22 June 2022

Back to top